Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan-Kettering Cancer Center about strategies and research surrounding optimized targeted therapy in melanoma.
Cancer Network spoke with Allison Betof Warner, MD, PhD, of Memorial Sloan Kettering Cancer Center, about long-term outcomes and responses to retreatment in patients with melanoma receiving anti-PD1 therapy.
Dr. Karen L. Reckamp on Germline Mutations and Onset of Lung Adenocarcinoma in Smokers and Nonsmokers
Cancer Network spoke with Karen L. Reckamp, MD, of City of Hope, about the link between several gene mutations and lung cancer in smokers vs nonsmokers.
Cancer Network spoke with Anna F.
Dr. Rimas Lukas on Controlled Interleukin-12 Combined With a PD-1 Inhibitor in Recurrent Glioblastoma
Cancer Network spoke with Rimas V. Lukas, MD, of Northwestern University Feinberg School of Medicine, about the combination of controlled interleukin-12 with a PD-1 inhibitor in recurrent glioblastoma.
Cancer Network spoke with Ahmad Tarhini, MD, PhD, about the results of the phase III United States Intergroup E1609 trial, presented at ASCO 2019.
Cancer Network spoke with Hope S. Rugo, MD, of the University of California, San Francisco, about the results of the phase III SOPHIA trial in HER2-positive breast cancer.
Cancer Network spoke with Ryan J. Sullivan, MD, of Massachusetts General Hospital, about the debate between immunotherapy sequencing vs targeted therapy for melanoma.
Cancer Network spoke with Mehmet Sitki Copur, MD, of Morrison Cancer Center, about his work in multiplex genomic testing as part of a 4-year experience in 2 community practices in central rural Nebraska.
Cancer Network spoke with Daniel George, MD, of Duke Health, about the treatment landscape and current trials for renal cell carcinoma.